Supplementary information

Supplementary Table 1. Additional references describing the JAK2 inhibitors presented in Table 1.

Inhibitor	References
LY2784544 - *Gandotinib*	(1)
CYT387 - *Momelotinib*	(2-7)
NS-018	(8, 9)
INCB028050 - *Baricitinib*	(10)
BMS-911543	(11, 12)
TG101348 - *Fedratinib*	(13)
SB1518 - *Pacritinib*	(14-16)
NVP-BVB808	(17)
TG101209	(18)
AG490	(19)
LS104	(20)

Supplementary Table 2. Additional references describing different types of kinase inhibitors presented in Table 2.

Inhibitor	References
PD184352 (MEK)	(21, 22)
Bivalent inhibitor (c-Src)	(23-25)
Neratinib (HER2) **Ibrutinib (BTK)**	(26, 27) (28)

References :

1. Verstovsek S, Mesa RA, Salama ME, Giles JLK, Pitou C, Zimmermann AH, et al. Phase I Study Of LY2784544, a JAK2 Selective Inhibitor, In Patients With Myelofibrosis (MF), Polycythemia Vera (PV), and Essential Thrombocythemia (ET) Blood. 2013;122(21):665.

2. Abdelrahman RA, Begna KH, Al-Kali A, Hogan WJ, Litzow MR, Tefferi A. Revised assessment of response and long-term discontinuation rates among 111 patients with myelofibrosis treated with momelotinib or ruxolitinib. Leukemia. 2015;29(2):498-500.

3. Pardanani A, Abdelrahman RA, Finke C, Lasho TT, Begna KH, Al-Kali A, et al. Genetic determinants of response and survival in momelotinib-treated patients with myelofibrosis. Leukemia. 2015;29(3):741-4.

4. Pardanani A, Gotlib JR, Gupta V, Roberts AW, Wadleigh M, Sirhan S, et al. Update On The Long-Term Efficacy and Safety Of Momelotinib, a JAK1 and JAK2 Inhibitor, For The Treatment Of Myelofibrosis. Blood. 2013;122(21):108.

5. Asshoff M, Warr M, Haschka D, Tymoszuk P, Petzer V, Demetz E, et al. The Jak1/Jak2 Inhibitor Momelotinib Inhibits Alk2, Decreases Hepcidin Production and Ameliorates Anemia of Chronic Disease (ACD) in Rodents. Blood. 2015;126(23):538-.

6. Tefferi A, Barraco D, Lasho TL, Begna KH, Al-Kali A, Hogan WJ, et al. Momelotinib Therapy in Myelofibrosis: 6-Years Follow-up Data on Safety, Efficacy and the Impact of Mutations on Overall and Relapse-Free Survival. Blood. 2016;128(22):1123-.

7. Warr M, Asshoff M, Zheng J, Sharma S, Maciejewski P, Weiss G, et al. Preclinical Modeling of ACVR1-Dependent Hepcidin Production and Anemia By Momelotinib. Blood. 2016;128(22):1967-.

8. Nakaya Y, Shide K, Niwa T, Homan J, Sugahara S, Horio T, et al. Efficacy of NS-018, a potent and selective JAK2/Src inhibitor, in primary cells and mouse models of myeloproliferative neoplasms. Blood Cancer J. 2011;1(7):e29.

9. Verstovsek S, Talpaz M, Ritchie EK, Wadleigh M, Odenike O, Jamieson C, et al. Phase 1/2 Study of NS-018, an Oral JAK2 Inhibitor, in Patients with Primary Myelofibrosis

(PMF), Post-Polycythemia Vera Myelofibrosis (postPV MF), or Post-Essential Thrombocythemia Myelofibrosis (postET MF). Blood. 2016;128(22):1936-.

10. Genovese MC, Kremer J, Zamani O, Ludivico C, Krogulec M, Xie L, et al. Baricitinib, An Oral Janus Kinase (JAK)1/JAK2 Inhibitor, in Patients with Active Rheumatoid Arthritis (RA) and an Inadequate Response to TNF Inhibitors: Results of the Phase 3 RA-Beacon Study Ann Rheum Dis. 2015;74(Suppl 2):75-6.

11. Roberts AW, Seymour JF, Burbury K, Verstovsek S, Tefferi A, Pardanani A. BMS-911543, A Selective JAK2 Inhibitor: A Multicenter Phase 1/2a Study In Myelofibrosis. Blood. 2013;122(21):664.

12. Wan H, Schroeder GM, Hart AC, Inghrim J, Grebinski J, Tokarski JS, et al. Discovery of a Highly Selective JAK2 Inhibitor, BMS-911543, for the Treatment of Myeloproliferative Neoplasms. ACS Med Chem Lett. 2015;6(8):850-5.

13. Pardanani A, Harrison C, Cortes JE, Cervantes F, Mesa RA, Milligan D, et al. Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial. JAMA Oncol. 2015;1(5):643-51.

14. Mesa RA, Egyed M, Szoke A, Suvorov A, Perkins A, Mayer J, et al. Results of the PERSIST-1 phase III study of pacritinib (PAC) versus best available therapy (BAT) in primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), or post-essential thrombocythemia-myelofibrosis (PET-MF). ASCO Annual Meeting: J Clin Oncol 33, 2015 (suppl; abstr LBA7006); 2015.

15. Puri A, Mahmood S, Maertens B, Davare M, Kurtz SE, Tognon CE, et al. Pacritinib Targets IRAK1 and Shows Synergy with HDAC and BET Inhibitors in Acute Myeloid Leukemia. Blood. 2016;128(22):3514-.

16. Vannucchi AM, Mead A, Egyed M, Szoke A, Suvorov A, Perkins A, et al. Relationship of JAK2 V617F Allelic Burden (AB) to Demographics, Disease Characteristics, and Response to Therapy in Persist-1, a Randomized Phase III Study of Pacritinib (PAC) Versus Best Available Therapy (BAT) in Patients (pts) with Primary and Secondary Myelofibrosis (MF). Blood. 2016;128(22):3131-.

17. Weigert O, Lane AA, Bird L, Kopp N, Chapuy B, van Bodegom D, et al. Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition. J Exp Med. 2012;209(2):259-73.

18. Pardanani A, Hood J, Lasho T, Levine RL, Martin MB, Noronha G, et al. TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations. Leukemia. 2007;21(8):1658-68.

19. Meydan N, Grunberger T, Dadi H, Shahar M, Arpaia E, Lapidot Z, et al. Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature. 1996;379(6566):645-8.

20. Kasper S, Breitenbuecher F, Hoehn Y, Heidel F, Lipka DB, Markova B, et al. The kinase inhibitor LS104 induces apoptosis, enhances cytotoxic effects of chemotherapeutic drugs and is targeting the receptor tyrosine kinase FLT3 in acute myeloid leukemia. Leuk Res. 2008;32(11):1698-708.

21. Lorusso PM, Adjei AA, Varterasian M, Gadgeel S, Reid J, Mitchell DY, et al. Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. J Clin Oncol. 2005;23(23):5281-93.

22. Ohren JF, Chen H, Pavlovsky A, Whitehead C, Zhang E, Kuffa P, et al. Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition. Nat Struct Mol Biol. 2004;11(12):1192-7.

23. Johnson TK, Soellner MB. Bivalent Inhibitors of c-Src Tyrosine Kinase That Bind a Regulatory Domain. Bioconjug Chem. 2016;27(7):1745-9.

24. Hill ZB, Perera BG, Maly DJ. A chemical genetic method for generating bivalent inhibitors of protein kinases. J Am Chem Soc. 2009;131(19):6686-8.

25. Hill ZB, Perera BG, Maly DJ. Bivalent inhibitors of the tyrosine kinases ABL and SRC: determinants of potency and selectivity. Mol Biosyst. 2011;7(2):447-56.

26. Burstein HJ, Sun Y, Dirix LY, Jiang Z, Paridaens R, Tan AR, et al. Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. J Clin Oncol. 2010;28(8):1301-7.

27. Chan A. Neratinib in HER-2-positive breast cancer: results to date and clinical usefulness. Ther Adv Med Oncol. 2016;8(5):339-50.

28. Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, Ghia P, et al. Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. New England Journal of Medicine. 2015;373(25):2425-37.